Do analysts prefer PASG or EXOZ?

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 178.95%. Given Passage Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Passage Bio is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PASG or EXOZ more profitable?

Passage Bio's return on equity of -218.59% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -218.59% -72.93% eXoZymes N/A -292.15% -158.66%

Do analysts prefer XLO or PASG?

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 178.95%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Is IMA or PASG more profitable?

ImageneBio's return on equity of -38.99% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Passage Bio N/A -218.59% -72.93%

Which has stronger earnings & valuation, PASG or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.32 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A

Is PASG or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -218.59% -72.93% MiNK Therapeutics N/A N/A -92.37%

Passage Bio (PASG) Competitors

$4.75 -0.29 (-5.75%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.82 +0.08 (+1.58%)

As of 09/18/2026 04:10 PM Eastern

Compare

PASG vs. EXOZ, XLO, IMA, INKT, and MCRB

Should you buy Passage Bio stock or one of its competitors? Passage Bio's main competitors and comparable companies include eXoZymes (EXOZ), Xilio Therapeutics (XLO), ImageneBio (IMA), MiNK Therapeutics (INKT), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Passage Bio compare to eXoZymes?

Passage Bio (NASDAQ:PASG) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

53.5% of Passage Bio shares are held by institutional investors. 4.9% of Passage Bio shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Passage Bio has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

In the previous week, Passage Bio's average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Passage Bio	Neutral
eXoZymes	Neutral

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 178.95%. Given Passage Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Passage Bio is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Passage Bio's return on equity of -218.59% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-218.59%	-72.93%
eXoZymes	N/A	-292.15%	-158.66%

eXoZymes has higher revenue and earnings than Passage Bio. eXoZymes is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A
eXoZymes	$70K	852.43	-$9.16M	-$1.19	N/A

Summary

Passage Bio beats eXoZymes on 7 of the 12 factors compared between the two stocks.

How does Passage Bio compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Passage Bio has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Passage Bio	N/A	-218.59%	-72.93%

Xilio Therapeutics has higher revenue and earnings than Passage Bio. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$1.64	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

In the previous week, Xilio Therapeutics had 1 more articles in the media than Passage Bio. MarketBeat recorded 1 mentions for Xilio Therapeutics and 0 mentions for Passage Bio. Xilio Therapeutics' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
Passage Bio	Neutral

Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 178.95%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Xilio Therapeutics beats Passage Bio on 8 of the 14 factors compared between the two stocks.

How does Passage Bio compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 493.05%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 178.95%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImageneBio is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, ImageneBio had 2 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for ImageneBio and 0 mentions for Passage Bio. ImageneBio's average media sentiment score of 0.34 beat Passage Bio's score of 0.00 indicating that ImageneBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImageneBio	Neutral
Passage Bio	Neutral

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ImageneBio has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

ImageneBio has higher revenue and earnings than Passage Bio. ImageneBio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	69.38	-$45.35M	-$4.58	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

ImageneBio's return on equity of -38.99% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Passage Bio	N/A	-218.59%	-72.93%

Summary

ImageneBio beats Passage Bio on 11 of the 15 factors compared between the two stocks.

How does Passage Bio compare to MiNK Therapeutics?

Passage Bio (NASDAQ:PASG) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

MiNK Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-218.59%	-72.93%
MiNK Therapeutics	N/A	N/A	-92.37%

Passage Bio presently has a consensus price target of $13.25, indicating a potential upside of 178.95%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 190.46%. Given MiNK Therapeutics' higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

In the previous week, Passage Bio's average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score.

Company	Overall Sentiment
Passage Bio	Neutral
MiNK Therapeutics	Neutral

Passage Bio has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Summary

Passage Bio beats MiNK Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Passage Bio compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Passage Bio has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Passage Bio	N/A	-218.59%	-72.93%

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 325.00%. Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 178.95%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Seres Therapeutics has higher revenue and earnings than Passage Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	50.89	$5.70M	-$2.43	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

In the previous week, Seres Therapeutics' average media sentiment score of 1.87 beat Passage Bio's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Very Positive
Passage Bio	Neutral

Seres Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Seres Therapeutics beats Passage Bio on 10 of the 13 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.28M	$3.89B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.42	14.23	275.21	25.38
Price / Sales	N/A	1,459.32	665.54	96.26
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	0.81	15.47	10.50	6.32
Net Income	-$45.52M	-$22.90M	$3.49B	$358.20M
7 Day Performance	-5.00%	-1.21%	0.59%	1.12%
1 Month Performance	6.03%	-3.29%	-1.74%	-2.39%
1 Year Performance	-33.75%	37.74%	18.13%	5.35%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	2.9594 of 5 stars	$4.75 -5.8%	$13.25 +178.9%	-33.8%	$15.28M	N/A	N/A	130	Gap Down
EXOZ eXoZymes	0.5304 of 5 stars	$6.59 -3.9%	N/A	-55.6%	$61.11M	$70K	N/A	29
XLO Xilio Therapeutics	0.0465 of 5 stars	$8.93 -0.8%	N/A	-16.4%	$58.73M	$43.77M	N/A	70	News Coverage Analyst Downgrade
IMA ImageneBio	2.8849 of 5 stars	$5.15 +6.2%	$29.00 +463.1%	-40.7%	$58.44M	$800K	N/A	70	Gap Up
INKT MiNK Therapeutics	1.9032 of 5 stars	$11.43 -1.8%	$35.00 +206.3%	-20.1%	$58.27M	N/A	N/A	30	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. EXOZ, XLO, IMA, INKT, and MCRB

How does Passage Bio compare to eXoZymes?

Summary

How does Passage Bio compare to Xilio Therapeutics?

Summary

How does Passage Bio compare to ImageneBio?

Summary

How does Passage Bio compare to MiNK Therapeutics?

Summary

How does Passage Bio compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. EXOZ, XLO, IMA, INKT, and MCRB

How does Passage Bio compare to eXoZymes?

Do institutionals & insiders believe in PASG or EXOZ?

Which has more risk and volatility, PASG or EXOZ?

Does the media favor PASG or EXOZ?

Do analysts prefer PASG or EXOZ?

Is PASG or EXOZ more profitable?

Which has better earnings & valuation, PASG or EXOZ?

Summary

How does Passage Bio compare to Xilio Therapeutics?

Is XLO or PASG more profitable?

Which has better earnings & valuation, XLO or PASG?

Does the media prefer XLO or PASG?

Which has more risk & volatility, XLO or PASG?

Do institutionals and insiders hold more shares of XLO or PASG?

Do analysts prefer XLO or PASG?

Summary

How does Passage Bio compare to ImageneBio?

Do analysts prefer IMA or PASG?

Does the media prefer IMA or PASG?

Do institutionals & insiders have more ownership in IMA or PASG?

Which has more risk and volatility, IMA or PASG?

Which has higher earnings & valuation, IMA or PASG?

Is IMA or PASG more profitable?

Summary

How does Passage Bio compare to MiNK Therapeutics?

Is PASG or INKT more profitable?

Do analysts prefer PASG or INKT?

Do insiders and institutionals hold more shares of PASG or INKT?

Which has stronger earnings & valuation, PASG or INKT?

Does the media favor PASG or INKT?

Which has more risk & volatility, PASG or INKT?

Summary

How does Passage Bio compare to Seres Therapeutics?

Is MCRB or PASG more profitable?

Do analysts rate MCRB or PASG?

Which has preferable earnings & valuation, MCRB or PASG?

Does the media refer more to MCRB or PASG?

Which has more risk and volatility, MCRB or PASG?

Do insiders & institutionals hold more shares of MCRB or PASG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools